Compare Globus Medical Inc. Class A Common Stock (GMED) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs RLX Technology Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while RLX Technology Inc trades at $1.7 (market cap $2.09B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 4.9× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.85% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and RLX Technology Inc for 36 Days on average.
| GMED | RLX | |
|---|---|---|
Market Cap | $10.25B | $2.09B |
Volume | 1,108,124 | 969,724 |
Sector | Health | Consumer Staples |
52-Week High | $96.82 | $2.57 |
52-Week Low | $58.33 | $1.68 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $9.76B | $817.70M |
Dividend Yield | — | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
RLX Technology trades at $1.71, down 0.58% with bearish technical signals. The stock recently hit 52-week lows despite solid fundamentals including $3.62B revenue and 21.87% net margin. Recent earnings missed expectations but international expansion shows growth potential. Technical indicators show selling pressure with bearish moving averages.
RLX presents a value opportunity with discounted valuation (P/E 15.34, P/B 0.9) but faces execution risks. The bearish technical trend and earnings misses offset strong cash flow and international growth. Investors should weigh the discounted valuation against recent price weakness and margin compression concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
